Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: - What side effects may happen from taking the study drug - To see effect of cemiplimab on the tumor - How much study drug is in the blood at different times
Official Title
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Alexander Ayon Valencia
650-498-5185
View on ClinicalTrials.gov
